thyroidectomy and in whether lymphadenectomy should be considered. B-type Raf kinase (BRAFV600E) mutation on exon 15 results from mutation in BRAF genes leading to the substitution of glutamic acid with valine at amino acid 600 (BRAFV600E mutation) on exon 15
Page:12
Helmi Khadra, Ahmed Deniwar, Khuzema Mohsin, Dominique Monlezun, and Emad Kandil
Luca Damiani, Sabrina Lupo, Roberta Rossi, Stefania Bruni, Mirco Bartolomei, Stefano Panareo, Paola Franceschetti, Paolo Carcoforo, Giovanni Lanza, Stefano Pelucchi, Ettore Degli Uberti, and Maria Chiara Zatelli
2012; 97: 4559–4570. 12 Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH, Cho BY, Park DJ: The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer
Neslihan Kurtulmus, Burak Ertas, Yesim Saglican, Hakan Kaya, Umit Ince, and Mete Duren
. Somatic point mutations that occur in the BRAF gene, which encodes serine/threonine protein kinase involved in this cascade, represent a significant genetic event in PTC [ 3 ]. Among these, the most common BRAF alteration is the V600E mutation (BRAF V600E
Sule Canberk, Joana C. Ferreira, Luísa Pereira, Rui Batısta, Andre F. Vieira, Paula Soares, Manuel Sobrinho Simões, and Valdemar Máximo
previous paper by TCGA Consortium on thyroid carcinoma (Table 1 B) [ 1 ]. Since PTC is a MAPK-driven cancer, the BRAF V600E and RAS gene (N-RAS, H-RAS, and K-RAS) mutations were also filtered from TCGA data for the entire dataset, in addition to
F. Cecoli, E.M. Ceresola, V. Altrinetti, M. Cabria, M. Cappagli, A. Montepagani, C.M. Cuttica, U. Filippi, D. Saverino, M. Raffa, M. Caputo, F. Minuto, M. Giusti, and M. Bagnasco
;25:300-307. 10.1089/thy.2014.0287 25386760 25 Virk RK, Van Dyke AL, Finkelstein Prasad A, Gibson J, Hui P, Theoharis CG, Carling T, Roman SA, Sosa JA, Udelsman R, Prasad ML: BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype
Chi-Yu Kuo, Po-Sheng Yang, Ming-Nan Chien, and Shih-Ping Cheng
. Association between obesity and BRAFV600E mutation status in patients with papillary thyroid cancer . Ann Surg Oncol . 2015 Dec ; 22 ( S3 Suppl 3 ): S683 – 90 . 10.1245/s10434-015-4765-z 26215201 1068-9265
Catherine Brophy, Rania Mehanna, Julie McCarthy, Antoinette Tuthill, Matthew S. Murphy, and Patrick Sheahan
benign, such cases should be kept under continued close follow-up. Possible future directions for the further work-up of Thy-3a cases may include the use of genetic analysis panels, including testing for BRAF-V600E mutation [ 32 , 33 , 34 , 35 ] and
Shigenobu Nagataki
, Suzuki K, Suzuki S, Yamashita S: BRAF(V600E) mutation is highly prevalent in thyroid carcinomas in the young population in Fukushima: a different oncogenic profile from Chernobyl. Sci Rep 2015;5:16976. 10.1038/srep16976 26584635
Carles Zafon, Juan J. Díez, Juan C. Galofré, and David S. Cooper
, Vezzosi V, Pazzagli M, Orlando C, Forti G: Circulating BRAFV600E in the diagnosis and follow-up of differentiated papillary thyroid carcinoma. J Clin Endocrinol Metab 2013;98:3359-3365. 23 Yu S, Liu Y, Wang J, Guo Z, Zhang Q, Yu F, Zhang Y, Huang K
Mohamed Abdouh, Roger Tabah, Vincenzo Arena, Manuel Arena, Zu-hua Gao, Aurelio Lorico, and Goffredo Orazio Arena
, mouse monoclonal CK20, mouse monoclonal thyroglobulin (all from DAKO), rabbit monoclonal CDX-2 (Cell Marque), and mouse monoclonal BRAFV600E (Abcam). Labeling was performed using iView DAB Detection Kit (Ventana) on the Ventana automated immunostainer
Page:12
